Pancreatic Cancer Research

ResearcherSeoul National UniversityNo recent work listed

Yoo Jin Choi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1142-1842; OpenAlex author ID A5070485039. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
56
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: 5 papers · 2022: 1 paper · 2023: 1 paper

Papers 9

  1. FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analy… Co-author DOI 10.1245/s10434-023-13353-2↗
  2. Preoperative carbohydrate antigen 19-9 and standard uptake value of positron emission tomography-computed tomography as prognostic markers in patients with pan… Co-author DOI 10.1002/jhbp.845↗
  3. Peritumoral lymph nodes in pancreatic cancer revisited; is it truly equivalent to lymph node metastasis? Co-author DOI 10.1002/jhbp.940↗
  4. Diagnostic model for pancreatic cancer using a multi-biomarker panel. Co-author DOI 10.4174/astr.2021.100.3.144↗
  5. CORRIGENDUM: Addition of data source: Diagnostic model for pancreatic cancer using a multi-biomarker panel. Co-author DOI 10.4174/astr.2021.100.4.252↗
  6. Comparison of perioperative short-term outcomes and oncologic long-term outcomes between open and laparoscopic distal pancreatectomy in patients with pancreati… Co-author DOI 10.4174/astr.2021.100.6.320↗
  7. Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX. Co-author DOI 10.5009/gnl20070↗
  8. The Role of Location of Tumor in the Prognosis of the Pancreatic Cancer. Co-author DOI 10.3390/cancers12082036↗
  9. Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer. Co-author DOI 10.1002/jhbp.648↗

Closest collaborators

The 25 strongest of 56 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hongbeom Kim · 9 shared papers, 2019–2023 · strength 1.07
  2. Yoonhyeong Byun · 8 shared papers, 2019–2022 · strength 0.95
  3. Jin‐Young Jang · 8 shared papers, 2019–2022 · strength 0.95
  4. Wooil Kwon · 8 shared papers, 2019–2022 · strength 0.95
  5. Jae Seung Kang · 7 shared papers, 2019–2021 · strength 0.78
  6. Jin Seok Heo · 2 shared papers, 2021 · strength 0.20
  7. Seungyeoun Lee · 2 shared papers, 2021 · strength 0.20
  8. Junghyun Namkung · 2 shared papers, 2021 · strength 0.20
  9. Taesung Park · 2 shared papers, 2021 · strength 0.20
  10. Woo Jin Lee · 2 shared papers, 2021 · strength 0.20
  11. Joo Kyung Park · 2 shared papers, 2021 · strength 0.20
  12. Chang Moo Kang · 2 shared papers, 2021 · strength 0.20
  13. Joon Oh Park · 2 shared papers, 2021 · strength 0.20
  14. Song Cheol Kim · 2 shared papers, 2021 · strength 0.20
  15. Do‐Youn Oh · 2 shared papers, 2019–2021 · strength 0.20
  16. Sang Hyub Lee · 2 shared papers, 2019–2021 · strength 0.20
  17. Ji Kon Ryu · 2 shared papers, 2019–2021 · strength 0.20
  18. Do Kyoon Moon · 1 shared paper, 2022 · strength 0.16
  19. Jung Min Lee · 1 shared paper, 2021 · strength 0.13
  20. Mirang Lee · 1 shared paper, 2020 · strength 0.12
  21. Matthew H. G. Katz · 1 shared paper, 2023 · strength 0.12
  22. Raëf Abdallah · 1 shared paper, 2023 · strength 0.12
  23. Jin‐Young Jang · 1 shared paper, 2023 · strength 0.12
  24. Giuseppe Malleo · 1 shared paper, 2023 · strength 0.12
  25. Gregory C. Wilson · 1 shared paper, 2023 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.